These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17998762)

  • 1. The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa.
    Ohwada R; Hotta M; Sato K; Shibasaki T; Takano K
    Endocr J; 2007 Dec; 54(6):953-9. PubMed ID: 17998762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintained malnutrition produces a progressive decrease in (OPG)/RANKL ratio and leptin levels in patients with anorexia nervosa.
    Muñoz-Calvo MT; Barrios V; García de Alvaro MT; Lefort M; Méndez-Dávila C; Argente J; de la Piedra C
    Scand J Clin Lab Invest; 2007; 67(4):387-93. PubMed ID: 17558893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Szapska B; Wołkowska-Pokrywa K; Dyduch A
    Bone; 2012 Jan; 50(1):156-60. PubMed ID: 22001124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.
    Zhao HY; Liu JM; Ning G; Zhao YJ; Chen Y; Sun LH; Zhang LZ; Xu MY; Chen JL
    Osteoporos Int; 2008 Feb; 19(2):221-6. PubMed ID: 17703270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Marek B; Świętochowska E; Kajdaniuk D; Strzelczyk J; Cieślicka A; Wołkowska-Pokrywa K; Kos-Kudła B
    Endokrynol Pol; 2015; 66(4):313-21. PubMed ID: 26323468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
    Piatek S; Adolf D; Wex T; Halangk W; Klose S; Westphal S; Amthauer H; Winckler S
    Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
    Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
    Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 10.  Dehydroepiandrosterone sulfate, osteoprotegerin and its soluble ligand sRANKL and bone metabolism in girls with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Wołkowska-Pokrywa K
    Postepy Hig Med Dosw (Online); 2012 Sep; 66():655-62. PubMed ID: 23001207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone metabolism, osteoprotegerin, receptor activator of nuclear factor-κB ligand and selected adipose tissue hormones in girls with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Świętochowska E; Marek B; Kajdaniuk D; Wołkowska-Pokrywa K; Kos-Kudła B
    Endokrynol Pol; 2014; 65(1):33-9. PubMed ID: 24549600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum osteoprotegerin in adolescent girls with anorexia nervosa.
    Misra M; Soyka LA; Miller KK; Herzog DB; Grinspoon S; De Chen D; Neubauer G; Klibanski A
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3816-22. PubMed ID: 12915674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
    Shaarawy M; Fathy SA; Mehany NL; Hindy OW
    Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis.
    Ambroszkiewicz J; Sands D; Gajewska J; Chelchowska M; Laskowska-Klita T
    Adv Med Sci; 2013; 58(2):338-43. PubMed ID: 24277958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Pavlidou V; Koukoulis G; Avramidis A
    Eur J Endocrinol; 2008 Mar; 158(3):411-5. PubMed ID: 18299476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.
    Gonnelli S; Montagnani A; Caffarelli C; Cadirni A; Campagna MS; Franci MB; Lucani B; Gaggiotti E; Nuti R
    J Endocrinol Invest; 2005 Jun; 28(6):534-9. PubMed ID: 16117195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
    Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
    Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
    Baek KH; Oh KW; Lee WY; Tae HJ; Rhee EJ; Han JH; Cha BY; Kim YJ; Lee KW; Son HY; Kang SK; Kim CC; Kang MI
    Bone; 2006 Dec; 39(6):1352-60. PubMed ID: 16905375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
    Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
    J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between osteoprotegerin (OPG), receptor activator of nuclear factor kappaB ligand (RANKL), and growth hormone (GH) secretory status in short children.
    Flint J; Wu S; Shott S; Suarez E; De Luca F
    J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1105-12. PubMed ID: 20333869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.